TheraMAB's Series B Round

TheraMAB raised a round of funding on February 16, 2012. Investors include Skolkovo Foundation.

TheraMAB is a biopharmaceutical company developing highly effective and broadly applicable immunotherapeutic monoclonal antibody. The company focuses on the development of potential drug that, by its …

Articles about TheraMAB's Series B Round: